Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Biotechnology

Healthcare
$2.83 +1.45%

+$0.04 today

Market cap
$1.76B
Beta
1.00
P/E (TTM)
-3.0
EPS (TTM)
-$1.06
52W Low $2.77High $7.18

Volume 41.13M

Average 15.60M

RXRX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Recursion Pharmaceuticals, Inc.NASDAQ: RXRX

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development declines year over year

Q2 FY2026 research & development of $89.61M fell 30.3% year over year, behind the -11.4% change in trailing-twelve-month research & development. Sequentially, it rose 2.0% from the prior quarter. Over 3 fiscal years it compounded at +39.8% a year.

Context

  • Research & development amounted to 569.4% of revenue in FY2025, up 35.1 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -30.3% toward the trailing-twelve-month pace of -11.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$89.61M+2.0% QoQ
Last fiscal yearDec 2025
$425.27M+35.3% YoY
LTMJun 2026
$381.91M-11.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.3%——
1 year+35.3%——
3-year CAGR+39.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
425.27M USD
Year-over-year change
+35.3%
4-year CAGR
+33.2%

Research & Development vs competitors

How RXRX compares with its peers on the latest reported figures

  • RXRX's LTM Jun 2026 research & development of $381.91M is the 2nd highest of the 4 companies compared; the peer median is $270.72M.
  • Its year-over-year change of -11.4% is the lowest of 4, against a peer median of -3.9%.
  • Research & development amounts to 696.2% of revenue for RXRX, versus a peer median of 2615.7%.
RXRX Competitors Peer median
Research & Development for RXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNLIDenali Therapeutics Inc.LTM Jun 2026$400.72M -3.9%+5.3%11118.8%
RXRXRecursion Pharmaceuticals, Inc.LTM Jun 2026$381.91M -11.4%+39.8%696.2%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$270.72M -4.1%+2.0%2615.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$114.57M +28.4%+7.1%572.9%
Peer median (excluding RXRX) $270.72M-3.9%+5.3%2615.7%

Competitors are the stored peer set for RXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10M39.68M43.88M58.84M74.68M
Cost of Revenue048.28M42.59M45.24M120.95M
Gross Profit10M(8.59M)1.29M13.6M(46.27M)
Gross Margin100.0%-21.7%2.9%23.1%-62.0%
Research & Development135.27M155.7M241.23M314.42M425.27M
Selling, General & Admin57.68M81.6M110.82M178.18M176.59M
Operating Expenses192.78M237.13M351.35M492.61M601.86M
Depreciation & Amortization8.41M11.76M24.4M36.49M83.7M
EBITDA(175.12M)(227.67M)(307.63M)(426.72M)(559.38M)
EBITDA Margin-1751.2%-573.7%-701.1%-725.2%-749.0%
Operating Income(182.78M)(245.73M)(350.06M)(479M)(648.13M)
Operating Margin-1827.8%-619.3%-797.8%-814.1%-867.9%
Interest Income73K6.25M19.12M15.76M22.79M
Interest Expense2.95M55K97K1.57M1.81M
Other Income / Expenses(3.7M)6.25M17.93M14.22M3.24M
Income Before Tax(186.48M)(239.48M)(332.13M)(464.79M)(644.9M)
Pre-Tax Margin-1864.8%-603.5%-757.0%-789.9%-863.5%
Income Tax Expense00(4.06M)(1.13M)(136K)
Net Income(186.48M)(239.48M)(328.07M)(463.66M)(644.76M)
Net Margin-1864.8%-603.5%-747.7%-788.0%-863.4%
EPS (Basic)(1.05)(1.36)(1.58)(1.69)(1.44)
EPS (Diluted)(1.05)(1.36)(1.58)(1.69)(1.44)
Weighted Avg Shares170.27M175.54M207.85M274.21M447.45M
Weighted Avg Shares (Diluted)170.27M175.54M207.85M274.21M447.45M

Recursion Pharmaceuticals, Inc.

NASDAQ:RXRX

Intrinsic Alpha fair value

Locked

Current Price

$2.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.